Moreover, there is the novel Bcl-2 inhibitory compound lisaftoclax (APG-2575) that is currently undergoing clinical evaluation upon FDA permission [41] and has been granted four Orphan Drug Designations (ODDs) by the FDA for the treatment of patients with AML, CLL, Waldenström macroglobulinemia (WM), and multiple myeloma (MM) [42]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.